(VIANEWS) – Shares of FibroGen (NASDAQ: FGEN) slid by a staggering 20% in 5 sessions from $20.4 at -20, to $16.32 at 16:09 EST on Wednesday, after two successive sessions in a row of losses. NASDAQ is jumping 0.36% to $11,842.01, after two successive sessions in a row of losses.
FibroGen’s last close was $16.39, 36.2% under its 52-week high of $25.69.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.21.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -258.01%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 10.3% and positive 12.8% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be overbought (>=80).
More news about FibroGen (FGEN).
